Thyroid cancer can be largely classified as well-differentiated, poorly differentiated, medullary and anaplastic. Differentiated thyroid cancer (DTC) includes follicular and papillary subtypes, with the incidence of papillary thyroid cancer (PTC) on the rise. The mainstay of treatment for DTC includes a combination of surgery, radioactive iodine (RAI) and levothyroxine suppression. DTC portends a favorable prognosis, even in the presence of distant metastases, with a 50% rate of 5-year survival largely due to tumor cell’s sensitivity to RAI therapy influencing disease outcome. In radioactive iodine refractory differentiated thyroid cancer (RAI-refractory DTC) there is a lower survival rate prompting the use of other therapeutic options available. RAI refractoriness is more common in older patients (age >40), large metastases and lesions that are fluorodeoxyglucose (FDG) avid on position emission tomography (PET). Over the past decade, Identification of genetic mutations in the signaling pathway involved in thyroid tumorigenesis has led to the approval of tyrosine kinase inhibitors (TKIs); Sorafenib and Lenvatinib in RAI-refractory DTC. Similarly, metastatic medullary thyroid cancer (MTC) implies an unfavorable 10-year survival rate of only 20% as the principal treatment options focuses on loco regional control via surgical and/or non-surgical options. The approval of TKIs such as Cabozantinib and Vandetanib has introduced an encouraging, novel, systemic therapeutic option for metastatic MTC. Lastly, anaplastic thyroid cancer (ATC) carries the worst prognosis with high recurrence rates. Treatment includes surgery, chemotherapy and external beam radiation. The FDA recently approved Dabrafenib plus trametinib for BRAF V600E mutated ATC. Considering the modality of chemotherapy and the expanding field of targeted therapies, the role of the oncologist and interaction with endocrinologist in the management of thyroid cancer needs further clarification aiming at collaborative management plans more than ever. This review summarizes the key phase III trials that led to the approval of TKIs in the treatment of DTC and metastatic MTC. Additionally, the review aims to clarify the patient selection criteria for initiation of TKIs and examine the implications, considerations and adverse effects prior to utilizing targeted therapy. Clinical trials are ongoing with promising results and may contribute to the addition of several targeted molecules and immune check point inhibitors to the therapeutic armamentarium for RAI-refractory DTC, medullary and anaplastic thyroid cancer.
Brain metastases from lung occur earlier, are more edematous, but fewer in number than those from breast cancers. Cerebellar brain metastases are more frequent in breast cancer.
Background: Sickle cell disease (SCD) is the most common inherited blood disorder in the United States, caused by polymerization of a mutated form of hemoglobin (HbS). HbS can form long polymers inside red blood cells (RBCs) that affect RBC shape and adhesion, resulting in RBC destruction, acute and chronic pain, inflammation and cumulative organ damage. SCD-101 is a botanical drug with in vitro and in vivo anti-sickling activity. The mechanism by which SCD-101 inhibits sickling is unknown; however, it does not bind directly to Hb or change the affinity of Hb for oxygen. We recently completed a dose-escalation clinical study of SCD-101 in adults with sickle cell disease in steady state, and other clinical studies are on-going. Methods: The initial prospective, open-label, Phase 1B dose-escalation study enrolled homozygous (SS) sickle cell patients and S/beta0 thalassemia patients ages 18-55 with baseline Hb levels 6.0-9.0 g/dL and hemoglobin F ≤10%. Admission within 30 days, transfusion within 90 days, and hydroxyurea within 6 months were exclusions. SCD-101 was dosed orally for 28-days with a 14-day follow-up visit. Doses administered during the dose escalation study were 550 mg, 1100 mg, 2200 mg and 4400 mg BID. The primary endpoint was safety, and the secondary endpoints were mean change in Hb, Hct, percent reticulocytes, LDH, indirect bilirubin, CRP, PROMIS fatigue questionnaire score, and percent circulating partially oxygenated sickle cells (POSCs) in venous whole blood fixed in 2% glutaraldehyde without exposure to air. A repeat cohort study is ongoing with dose adjusted to 2750 mg TID, a 6-minute walk test added as a functional endpoint and measurement of inflammatory cytokines by ELISA to explore the effect of SCD-101 on inflammation. Results: As of August 4, 2016, 26 patients with sickle cell disease have been enrolled, 20 patients have completed the 28-day dose-escalation study and 3 were discontinued before receiving their first dose of SCD-101. Three patients are enrolled in the 28-day repeat cohort study. There have been no dose reductions or interruptions due to drug-related effects. SCD-101 was generally well-tolerated with mild-moderate bloating and flatulence at the highest dose on a BID schedule in the dose-escalation study, which were not observed with a TID schedule in the repeat cohort study. There were no significant changes in safety laboratory tests and no significant changes in hemoglobin, hematocrit, LDH, unconjugated bilirubin, or reticulocytes. No significant changes were observed in renal, hepatic or other safety chemistries or electrocardiograms. SCD-101 participants treated at higher doses reported a decrease in chronic pain and fatigue after 7-14 days, which returned post-treatment when measured on the 14-day follow-up visit. Participants at the two highest doses reported an increase in exercise capacity and an improvement in sleep. Two participants with ankle ulcers, enrolled at the two highest doses, showed improved healing. Analysis of peripheral blood smears revealed an improvement in the shape of circulating RBCs. There was no change in inflammatory cytokines in the first 7 days in the repeat cohort study, though the Day 28 data may show a different result. Conclusions: SCD-101 is a promising new drug for the treatment of sickle cell disease, based on the results from the studies reported here. SCD-101 was well tolerated over an 8-fold dose range, and dose-dependent anti-sickling effects on RBC were observed, though without significant changes in hemolysis. Clinical benefits included reduced chronic pain and fatigue, improved sleep and improved ulcer healing. While the identity of the active substance(s) in SCD-101 and the mechanism(s) of action are unknown, SCD-101 has a direct anti-sickling effect on RBCs, compatible with an intracellular or membrane effect on RBCs. We hypothesize that the observed effects could be explained by increased vascular flow or increased oxygen delivery or a reduction in inflammation. A placebo-controlled crossover study will be completed in 2016 including a 6-minute walk test as a primary clinical endpoint, and a multi-site Phase 2 study is planned for 2017. As a botanical drug, SCD-101 may be a useful treatment for sickle cell disease worldwide. Disclosures Swift: Global Blood Therapeutics: Equity Ownership; Mast Therapeutics: Equity Ownership; SCD Development: Employment, Equity Ownership.
Patients with cervical adenopathy suspicious for malignancy are often referred to the Otolaryngology Service for tissue diagnosis. Confirmation of nodal involvement by upper aero-digestive tract tumors (UADT) is best obtained by fine needle aspiration (FNA). Reported studies of FNA for lymphoma diagnosis have yielded conflicting results. Retrospective review of charts and pathology of 161 patients diagnosed with lymphomas yielded 53 patients with cervical adenopathy without apparent UADT. FNA's were performed on 28, and were repeated nine times, for a total of 37. Eleven had Hodgkin's disease and 17 other types of lymphomas. Seven of 37 specimens contained only blood; 15 contained lymphoid cells, nine of which were designated "reactive." Lymphoid cells designated as "atypical" or "suspicious for lymphoma" were found in 13 of the 37 aspirates. Two were diagnostic of lymphoma. Lymphoma was confirmed by histopathologic specimens in all patients, obtained 0-941 days (median 15, mean 73 days) after initial FNA. In lymphoma patients with cervical lymphadenopathy, FNA does not usually suffice for, and often leads to significant delays in diagnosis.
Hydroxyurea (HU) is a commonly used medication for myeloproliferative neoplasm (MPN) and is usually well tolerated. Cutaneous toxicity of HU is well known and can be seen in several manifestations. We report a case of a man with MPL gene mutation associated with essential thrombocytosis, who had a rare mucocutaneous toxicity with diffuse tongue, skin and nail discoloration. Mucocutaneous toxicity is usually a benign condition and self-resolves after discontinuation of the medication. It can lead to patient anxiety and medication discontinuation. The mechanism for development of HU-induced mucocutaneous hyperpigmentation is poorly understood.
We describe a case of a 63-year-old woman with advanced colon cancer and liver metastases who was treated with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and cetuximab chemotherapy. She tolerated 13 cycles of chemotherapy without any significant hematological side effects, but after the 14th cycle, she developed melena and was admitted for severe thrombocytopenia. After supportive care, the platelet counts rapidly improved to 76,000/μL. Upon initiation of FOLFIRI and cetuximab chemotherapy, she again developed rectal bleeding and severe thrombocytopenia with a platelet count of 6000/μL. Lab testing was positive for oxaliplatin and irinotecan drug-dependent platelet antibodies on flow cytometry assay. Drug-induced thrombocytopenia (DITP) is associated with several classes of drugs with several proposed underlying mechanisms. Prospective studies are needed to further address different mechanisms of drug-induced thrombocytopenia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.